Hutchison China MediTech Limited

HCM11 Dec 2024
Healthcare
$17.18
-0.04 (-3.76%)
Lowest Today
$16.86
Highest Today
$17.24
Today’s Open
$17.18
Prev. Close
$17.54
52 Week High
$21.92
52 Week Low
$11.93
To Invest in Hutchison China MediTech Limited

Hutchison China MediTech Limited

Healthcare
HCM11 Dec 2024
-0.04 (-3.76%)
1M
3M
6M
1Y
5Y
Low
$16.86
Day’s Range
High
$17.24
16.86
52 Week Low
$11.93
52-Week Range
52 Week High
$21.92
11.93
1 Day
-
1 Week
-0.41%
1 month return
-3.64%
3 month return
+0.53%
6 month return
-5.15%
1 Year return
-8.44%
3 Years return
-48.71%
5 Years return
-26.24%
10 Years return
-
Institutional Holdings
Schroder Investment Management Group
1.71
Allianz Asset Management AG
0.78
Schroder ISF Hong Kong Eq C Acc HKD
0.67
Allianz Oriental Income P USD
0.54
Schroder Asian Growth SGD A Dis
0.52
State Street Corp
0.2
AIA Group Ltd
0.18

Market Status

Fundamentals
Market Cap
2998.22 mln
PB Ratio
3.94
PE Ratio
0
Enterprise Value
2321.99 mln
Total Assets
1279.77 mln
Volume

Company Financials

Fund house & investment objective

Company Information
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
Organisation
Hutchison China MediTech Limited
Employees
1970
Industry
Drug Manufacturers - Specialty & Generic
CEO
Dr. Wei-Guo  Su B.Sc., Ph.D.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step